PatentsUSA
US Jury Orders Amgen to Pay $20.2 Million in Antibody Patent Infringement Case
A US jury has ruled that Amgen must pay $20.2 million in damages for infringing an antibody patent. The verdict underscores ongoing patent enforcement challenges in the biopharmaceutical sector, highlighting the high stakes involved in antibody-related intellectual property disputes.
Friday, June 12, 2026